AXSM AXSOME THERAPEUTICS

Axsome Therapeutics to Participate in Investor Conferences in September

Axsome Therapeutics to Participate in Investor Conferences in September

Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York

Wells Fargo Healthcare Conference on September 5 in Boston

Baird 2024 Global Healthcare Conference on September 11 in New York

Cantor Global Healthcare Conference on September 18 in New York

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will participate in four investor conferences in September:

  • Morgan Stanley 22nd Annual Global Healthcare Conference

    The Company will present on Wednesday, September 4, 2024 at 4:50 p.m. ET in New York, NY
  • 2024 Wells Fargo Healthcare Conference

    The Company will participate in investor meetings on Thursday, September 5, 2024 in Boston, MA
  • Baird 2024 Global Healthcare Conference

    The Company will present on Wednesday, September 11, 2024 at 8:30 a.m. ET in New York, NY
  • 2024 Cantor Global Healthcare Conference

    The Company will present on Wednesday, September 18, 2024 at 9:45 a.m. ET in New York, NY

Live webcasts of the presentations at the Morgan Stanley and Cantor conferences can be accessed on the Investors page of the Company’s website at Replays of the webcasts will be available for approximately 30 days following each event.

About Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at

Investors:

Mark Jacobson

Chief Operating Officer

(212) 332-3243

Media:

Darren Opland

Director, Corporate Communications

(929) 837-1065



EN
27/08/2024

Underlying

AXSMAXSOME THERAPEUTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AXSOME THERAPEUTICS

 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Euro...

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations on AXS-12 and solriamfetol at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society, being ...

September 24, 2024 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for A...

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine FDA sets PDUFA action goal date of January 31, 2025 NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Company’s New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. The FDA designated ...

September 4, 2024 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics to Participate in Investor Conferences in Septembe...

Axsome Therapeutics to Participate in Investor Conferences in September Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York Wells Fargo Healthcare Conference on September 5 in Boston Baird 2024 Global Healthcare Conference on September 11 in New York Cantor Global Healthcare Conference on September 18 in New York NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will participate in...

August 27, 2024 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol...

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc. NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has reached agreement with Sandoz Inc. (Sandoz) to dismiss the patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which was pending in the United States District Court for the District of New Jersey, resulted from sub...

August 21, 2024 1 EN
 PRESS RELEASE
Free
AXSM AXSOME THERAPEU...

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and ...

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 in migraine resubmitted Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer’s disease agitation anticipated 2H 2024 Topline results of ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 ...

August 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch